Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 5 drugs
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl...
Approved
Investigational
Matched Description: … or a rituximab-containing regimen. ... B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab ... is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E.[Label] This medication was granted accelerated FDA approval on 10 June 2019.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally...
Approved
Matched Synonyms: … Rituximab ... rituximab-abbs ... rituximab-arrx …
Matched Name: … Rituximab
Matched Description: … sequences and human constant region sequences [A40017], [FDA label]. ... Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the ... On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808 …
Matched Categories: … rituximab ... Amino Acids, Peptides, and Proteins …
Matched Products: … Truxima®(rituximab) 10mg/ml Concentrate for Solution for Infusion …
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Matched Description: … and toxicities. ... exists as a racemic mixture of the active S(-) and R(+) forms. ... [A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic ... [L12612] Although it has a similar molecular mechanism of action as [rituximab], another CD-20 monoclonal ... mouse and hybridoma technology. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying all 5 drugs